In the decade since the Doha Declaration was adopted, significant progress has been made in addressing problems associated with innovation and access to medicines, including through expanded financial support for procurement and distribution of treatments and vaccines and the establishment of...

In August 2001 the first public meeting of the American Society of International Law Project on Human Rights and International Trade (‘Project’) was held at the World Trade Institute in Berne, Switzerland. One session of that meeting was devoted to the relationship between human rights and...

These are neither the best of times nor the worst of times for the pharmaceutical industry, or for global public health. Media reports regarding recent legal developments would suggest that the originator pharmaceutical industry is facing a new and dangerous threat to its long-term welfare,...

This chapter addresses the interface between health and intellectual property (IP). The chapter provides an introduction to the forms of IP principally as they relate to health products, and describes the international legal framework in which IP is situated. It addresses the ways in which IP...

UNDP first drew attention to the utility of competition law in health care as a tool to facilitate and promote access to health technologies in 2014. It published ‘Using Competition Law to Promote Access to Health Technologies: A guidebook for low- and middle-income countries’ (the...

There are some important reasons why low- and middle-income countries (LMICs) may choose to make greater use of competition law and policy to reduce the cost of treatment. First, multilateral trade rules allow substantial flexibility in the development and application of competition law and...